Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – Biotechnology company Genzyme Corp. could be the subject of a bidding war, and GlaxoSmithKline (NYSE: GSK) might be one of the bidders, according to the Wall Street Journal.

GSK has been reported to be on the prowl for acquisitions, and news broke Friday that Sanofi-Aventis, led by former GSK executive Chris Viehbacher, could buy Genzyme.

On Monday, the Journal reported that GSK and Johnson & Johnson “are seen as the most logical suitors for Genzyme.

“Sanofi’s interest in Genzyme could spark a bidding war, as many of these industry behemoths,” the newspaper reported.

GSK maintains its U.S. headquarters in RTP.

Read the WSJ report (Subscription required for full access.)

Get the latest news alerts: at Twitter.